Genprex Inc (NASDAQ: GNPX) is having a relatively strong start to the trading session this morning, and for good reason. The company provided a clinical and corporate update, leading to excitement among investors who are reacting by pushing the stock upward. Today, we’ll talk about:
- The update;
- what we’re seeing from GNPX as a result;
- and what we’ll be watching for ahead.
GNPX Provides Clinical And Corporate Update
As mentioned above, Genprex is having a relatively strong day in the market today after announcing a clinical and corporate update. During the update, the company outlined the groundwork that it has been laying in order to enjoy a strong 2018 year and more. In the update, the company pointed to key progress on Oncoprex, a cancer treatment being developed by GNPX. To learn more, click here to read the full update! In a statement, Rodney Varner, Chairman and CEO at GNPX, had the following to offer:
2017 was a pivotal year for Genprex, laying the groundwork for 2018 and beyond. We are dedicated to developing our novel therapeutic candidate, Oncoprex™, as a potential new treatment for non-small cell lung cancer and look forward to advancing Oncoprex in combination with targeted therapy and immunotherapy drugs through clinical trials.
The above statement was followed up by Julien L. Pham, MD, MPH, President and COO at GNPX, had the following to offer:
We believe that Oncoprex may provide medical benefit in several subpopulations of NSCLC for which there is an unmet medical need and may provide pathways for expedited approval by the FDA.
What We’re Seeing From The Stock
With the news that Genprex is progressing in a strong way with regard to its clinical programs, it’s no surprise that investors are happy. That happiness can be seen in the value of the stock as it makes its way upward in the market today. At the moment (10:38), GNPX is trading at $5.17 per share after a gain of $0.044 per share or 0.86% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on GNPX. In particular, we’re interested in following the story surrounding the company’s work with regard to Oncoprex. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!